Seer, Inc. is a life sciences company. The Company is engaged in developing transformative products that open a new gateway to the proteome. Its product, the Proteograph Product Suite (Proteograph), leverages its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid and large-scale access to the proteome. The Proteograph Product Suite is an integrated solution that includes consumables, an automation instrument and software. Its proprietary engineered NPs provide unbiased sampling of intact proteins across the dynamic range of the proteome, capturing molecular information at the peptide-level, including protein variants. It is focused on driving the adoption of the Proteograph by customers in the proteomics and genomics markets. The Proteograph Product Suite is an integrated solution consisting of consumables, an automation instrument, and software to perform biased, deep proteomic analysis at scale in a matter of hours.
企業コードSEER
会社名Seer Inc
上場日Dec 04, 2020
最高経営責任者「CEO」Dr. Omid C. Farokhzad, M.D.
従業員数134
証券種類Ordinary Share
決算期末Dec 04
本社所在地3800 Bridge Parkway, Suite 102
都市REDWOOD CITY
証券取引所NASDAQ Global Select Consolidated
国United States of America
郵便番号94065
電話番号16504530000
ウェブサイトhttps://seer.bio/
企業コードSEER
上場日Dec 04, 2020
最高経営責任者「CEO」Dr. Omid C. Farokhzad, M.D.
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし